London, 29 May 2015: Technavio, the independent tech-focused global research firm, has published a report on the global benign prostatic hyperplasia devices market 2015-2019, which is expected to grow at a CAGR of 5.05% during the forecast period of 2014-2019.
“The introduction of anesthesia and improved, simpler, and safer procedures have led to a paradigm shift from inpatient surgeries to same-day outpatient procedures,” says Faisal Ghaus, Vice President of Technavio.
“Cost effectiveness and convenience are the two major advantages of these procedures. TURP and TUMT are procedures that can be performed on an outpatient basis.”
Key Market Drivers
- Growing elderly population
- Increased use of MI procedures
- Favorable reimbursement scenario
- Untapped market in emerging countries
Key Market Trends
- High number of outpatient procedures
- Increased use of TURP
- Growing popularity of laser enucleation
- Rise in use of prostatic stents
Key Market Vendors
- Endo International plc
- Karl Storz GmbH & Co. KG
- Lumenis Ltd.
- Olympus Corp.
- Urologix Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
